TY - JOUR
T1 - Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer
T2 - a clinical practice guideline
AU - Freyer, David R.
AU - Brock, Penelope R.
AU - Chang, Kay W.
AU - Dupuis, L. Lee
AU - Epelman, Sidnei
AU - Knight, Kristin
AU - Mills, Denise
AU - Phillips, Robert
AU - Potter, Emma
AU - Risby, Demie
AU - Simpkin, Philippa
AU - Sullivan, Michael
AU - Cabral, Sandra
AU - Robinson, Paula D.
AU - Sung, Lillian
N1 - Funding Information:
The Pediatric Oncology Group of Ontario provided funding but did not influence the content of this manuscript or the decision to submit for publication. LS is supported by a Canada Research Chair in Pediatric Oncology Supportive Care.
Funding Information:
DRF has received financial support from Sensorion for his consulting time and expertise, and his hospital has received research support from Otonomy for site participation in a clinical trial. PRB has received consulting fees from Fennec Pharma. KWC has received financial support from Otonomy for travel expenses to attend an event to discuss a multi-institutional trial of a possible otoprotectant. MS was a principal investigator for a clinical trial and has published a commentary on ototoxicity. All other authors declare no competing interests.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/2
Y1 - 2020/2
N2 - Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with cancer, we convened an international, multidisciplinary panel of experts and patient advocates to update a systematic review of randomised trials for the prevention of cisplatin-induced ototoxicity. The systematic review identified 27 eligible adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, and cisplatin infusion duration. Regarding systemic sodium thiosulfate, the panel made a strong recommendation for administration in non-metastatic hepatoblastoma, a weak recommendation for administration in other non-metastatic cancers, and a weak recommendation against its routine use in metastatic cancers. Amifostine, sodium diethyldithiocarbamate, and intratympanic therapy should not be routinely used. Cisplatin infusion duration should not be altered as a means to reduce ototoxicity. Further research to determine the safety of sodium thiosulfate in patients with metastatic cancer is encouraged.
AB - Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with cancer, we convened an international, multidisciplinary panel of experts and patient advocates to update a systematic review of randomised trials for the prevention of cisplatin-induced ototoxicity. The systematic review identified 27 eligible adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, and cisplatin infusion duration. Regarding systemic sodium thiosulfate, the panel made a strong recommendation for administration in non-metastatic hepatoblastoma, a weak recommendation for administration in other non-metastatic cancers, and a weak recommendation against its routine use in metastatic cancers. Amifostine, sodium diethyldithiocarbamate, and intratympanic therapy should not be routinely used. Cisplatin infusion duration should not be altered as a means to reduce ototoxicity. Further research to determine the safety of sodium thiosulfate in patients with metastatic cancer is encouraged.
UR - http://www.scopus.com/inward/record.url?scp=85078083132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078083132&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(19)30336-0
DO - 10.1016/S2352-4642(19)30336-0
M3 - Review article
C2 - 31866182
AN - SCOPUS:85078083132
SN - 2352-4642
VL - 4
SP - 141
EP - 150
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
IS - 2
ER -